US Stock MarketDetailed Quotes

RARE Ultragenyx Pharmaceutical

Watchlist
  • 41.150
  • -0.920-2.19%
Close Jan 2 16:00 ET
  • 41.150
  • 0.0000.00%
Post 20:01 ET
3.80BMarket Cap-6.48P/E (TTM)

Ultragenyx Pharmaceutical Key Stats

Ultragenyx Pharmaceutical Q3 2024 Earnings Date

Currency:USDNov 5, 2024

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
135.25M
139.49M
+4.25M
Beat Est.
+37.93%
+42.27%
+3.14%
EPS
-1.48
-1.40
+0.08
Beat Est.
+33.46%
+37.22%
+5.65%
Strong Buy

Jan 2, 2025

Ultragenyx Pharmaceutical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 11 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 146.336M--
--2024/Q4-- / 143.738M--
Nov 5, 20242024/Q3139.494M / 135.247M--
Aug 1, 20242024/Q2147.026M / 123.214M--
May 2, 20242024/Q1108.833M / 116.438M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 146.336M--
--2024/Q4-- / 143.738M--
Nov 5, 20242024/Q3139.494M / 135.247M--
Aug 1, 20242024/Q2147.026M / 123.214M--
May 2, 20242024/Q1108.833M / 116.438M--

Unlock Free Earnings Estimates

Ultragenyx Pharmaceutical Earnings Reports

Read more

Trending US Stocks
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Jan 2, 2025

Strong Buy

  • Buy

    100.00%
  • Hold

    0.00%
  • Sell

    0.00%

Price Target

No Data